Dr. Reddys Laboratories Ltd 2019 AR2
The report highlights Dr. Reddy's Laboratories Limited's operational and financial turnaround for the fiscal year 2018-19, with consolidated revenues reaching ₹154 billion, an 8% increase from the previous year. The company achieved significant growth in branded generics markets, particularly in India, Russia, and emerging markets, which offset pricing pressures in the US. Key strategic initiatives included launching the trastuzumab biosimilar Hervycta® in India and a generic version of Suboxone® in the US to treat opioid addiction. Additionally, the company advanced its digital transformation with the launch of the B2B customer service portal XCEED and made progress in environmental sustainability, avoiding 46,473 tons of CO2e through solar energy consumption.
Company: Dr. Reddys Laboratories Ltd
Sector: Health Care
Country: India
Year: 2019
Type: AR2
Pages: 284
Back to company
Dr. Reddys Laboratories Ltd
Annual Report
The report highlights Dr. Reddy's Laboratories Limited's operational and financial turnaround for the fiscal year 2018-19, with consolidated revenues reaching ₹154 billion, an 8% increase from the previous year. The company achieved significant growth in branded generics markets, particularly in India, Russia, and emerging markets, which offset pricing pressures in the US. Key strategic initiatives included launching the trastuzumab biosimilar Hervycta® in India and a generic version of Suboxone® in the US to treat opioid addiction. Additionally, the company advanced its digital transformation with the launch of the B2B customer service portal XCEED and made progress in environmental sustainability, avoiding 46,473 tons of CO2e through solar energy consumption.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees